BIIB

Biogen Inc.

Phase 2 AI-extracted

EMPAVELI

C3 glomerulopathy (C3G) or primary IC-MPGN

720d ago Aug 31, 2024

SEC 8-K verified 2mo ago

Countdown card →

BIIB

BIOGEN

Approval Confirmed

Spinraza

147d ago Mar 27, 2026

openFDA verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

PDUFA Confirmed

SPINRAZA

140d ago Apr 3, 2026

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

PDUFA Confirmed

LEQEMBI IQLIK

89d ago May 24, 2026

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen

Phase 3 Estimated

Litifilimab

Subacute Cutaneous Lupus Erythematosus

T-minus 60 days Oct 20, 2026

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen

Phase 3 Estimated

Felzartamab

Immunoglobulin A Nephropathy (IgAN)

T-minus 283 days May 31, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

Phase 2 AI-extracted

SYFOVRE

geographic atrophy secondary to age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

Phase 3 AI-extracted

SYFOVRE

geographic atrophy secondary to age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

Approval AI-extracted

SYFOVRE

geographic atrophy secondary to age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

Approval AI-extracted

EMPAVELI

C3 glomerulopathy (C3G) or primary IC-MPGN

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

BIIB

Biogen Inc.

Phase 3 AI-extracted

EMPAVELI

C3 glomerulopathy (C3G) or primary IC-MPGN

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →